This trial is evaluating whether Quality-of-Life Assessment will improve 1 primary outcome and 1 secondary outcome in patients with Carcinoma in Situ. Measurement will happen over the course of From day 1 to day 180.
This trial requires 545 total participants across 2 different treatment groups
This trial involves 2 different treatments. Quality-of-Life Assessment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The most common causes of carcinoma, mammary ductal are [increased estrogen receptor α (ERα): estrogen (E2) receptor status (ERα or ERβ) and overexpression of the proto-oncogene HER2/neu] (http://www.ncbi.nlm.nih.gov/books/NBK.fcgi?rid=cis_bibl_220.127.116.11.1). Breast density has a relationship to HER2/neu(rs11899360) (http://genetics.humc.u-psud.fr/humc/genetic-path/path_her2/humc_her2." - Anonymous Online Contributor
"Symptoms of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) involve breast tenderness, lumps or masses, nipple discharge, altered skin colour, and changes in shape to the breast. The presence of one of these symptoms, or any combination of symptoms, increases the risk of breast cancer to 4.9 fold over the general population." - Anonymous Online Contributor
"The American Cancer Society's estimate of 35,740 new cases of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in 2016 is consistent with the number of new cases previously calculated based on breast cancer rates observed in the US in 2010. Estimates of new cases of breast cancer based on rates of breast cancer in 2010 suggest that about 15,000 new cancers will occur in the United States in 2016. This suggests that about 75,000 new cancers will be diagnosed in the United States in 2016." - Anonymous Online Contributor
"Mammary ductal carcinomas occur most commonly in postmenopausal women. A substantial proportion have metastases and in most cases have advanced-stage disease. Radical mastectomy without axillary dissection is typically undertaken and often followed by adjuvant chemotherapy. The adjuvant chemotherapy usually includes anthracyclines." - Anonymous Online Contributor
"Cancer, mammary ductal is a condition that mostly affects women between age 60 and 90. This condition is associated with the development of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) later in life and is caused when cells from a benign lesion or tumor develop uncontrollable cell growth. The most common of all breast cancer is carcinoma, mammary ductal. Breast cancer is one of the most effective cancer treatments, even when it is discovered at an early stage. Copyright rights © 2015 Medical Publishers International." - Anonymous Online Contributor
"The authors have analyzed the treatment history of patients who present with mammary carcinoma to the authors' institution, and have determined that (1) most patients did not receive optimal therapy but had some form of treatment, (2) most patients had good cosmetic results after surgery, and (3) the number of patients with residual disease who received chemotherapy was small, and the number of patients who had failed or lost residual disease was also small when compared with the number of patients with residual disease who received chemotherapy." - Anonymous Online Contributor
"A small percentage of patients who have carcinoma, mammary ductal and are not eligible for clinical trial would be appropriate candidates for treatment by clinical trial. Although the probability of treatment success may be low, the likelihood that not every patient with carcinoma in situ or carcinoma with microinvasion will progress to invasive carcinoma may be increased with early screening and treatment by clinical trial. Clinical trials involving long-term follow-up might be appropriate for patients who are candidates for treatment of in situ carcinoma by surgical resection." - Anonymous Online Contributor
"Most people with operable breast, skin and breast cancer can engage in quality-of-life assessment. If asked to complete specific self-report items the data obtained appear comparable to the data obtained by a health professional observer (health care provider)." - Anonymous Online Contributor
"Quality-of-life assessments were frequently reported using PQI, but other sources of assessments appeared more often. This would indicate that quality of life assessments are not being routinely used in practice, particularly in primary care settings." - Anonymous Online Contributor
"In a recent study, findings of our study indicate that QoL can be used to characterize the course of breast cancer and to identify patients at risk of developing complications due to surgery, chemotherapy, and endocrine therapy. In particular, we demonstrated that quality of life correlates with clinical symptomatology in patients suffering from breast cancer." - Anonymous Online Contributor
"Patients with carcinoma (C) have markedly different levels of health-related quality of life (HRQOL) than those with benign breast disease (BI). The significant differences between C and BI in HRQOL scores suggest that patients should be evaluated separately before inclusion in clinical studies. Furthermore, HRQOL assessment should be an integral part of patient selection and quality-of life outcomes should be routinely measured." - Anonymous Online Contributor
"Based on these findings, we recommend that the use of definitive radiation therapy in carcinoma, ductal, should be considered if a pathological evaluation confirms the presence of invasive disease." - Anonymous Online Contributor